YKYong Tae Kwak

Yong Tae Kwak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yong Tae Kwak has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • YoungSoon Yang

    Soonchunhyang University College of Medicine, Cheonan Hospital

    25 shared publications
  • YoungSoon Yang

    Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea

    11 shared publications
  • Min-Seong Koo

    Department of Psychiatry, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Seo-gu, Incheon, Republic of Korea

    10 shared publications
  • Youngsoon Yang

    Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Chungcheongnam, 31151, Korea

    4 shared publications
  • Ki Jin Jung

    Department of Orthopedic Surgery, Soonchunhyang University , Cheonan-si, Chungcheongnam-do 31151

    3 shared publications
  • Miju Cheon

    Department of Nuclear Medicine, Veterans Health Service Medical Center, Seoul, Korea

    2 shared publications

Latest Publications

  • Neuropsychiatric symptom-role reorganization in amyloid PET-positive Alzheimer's disease: An expanded-cohort analysis

    by YoungSoon Yang, Yong Tae Kwak

    Background: Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) often occur in clusters, and their clinical meaning may depend on the symptoms with which they co-occur. Whether a previously identified NPS cluster pattern remains transportable after expansion of an amyloid PET-positive cohort is uncertain. Objective: To assess the transportability of a previously published NPS cluster model and to characterize symptom-role reorganization after cohort expansion. Methods: We analyzed 301 consecutive drug-naive patients with probable AD and positive 18 F-FC119S amyloid PET. The cohort comprised the previously published 143-patient reference cohort and 158 newly enrolled, non-overlapping patients who constituted the extension cohort. Twelve Korean Neuropsychiatric Inventory domains were coded as present or absent. Hierarchical clustering was repeated in the extension cohort and in the full cohort, and changes in individual symptom relationships were examined. Results: The original four-cluster solution was only partly reproduced. Aggression, disinhibition, and aberrant motor behavior remained closely grouped, while anxiety and irritability also remained linked and were joined by euphoria. Hallucination shifted into the behavioral-dyscontrol cluster, whereas depression, apathy, nighttime behavior, and eating abnormality formed a vegetative-apathy cluster. Delusion formed a single-domain cluster and, together with aggression, aberrant motor behavior, and disinhibition, showed the largest stage-associated prevalence differences between Clinical Dementia Rating (CDR) 0.5 and CDR 1.0–2.0. Conclusions: NPS clusters in amyloid PET-positive AD may not represent fixed syndromes. A symptom-role framework that distinguishes preserved relationships, reorganized symptoms, and independent stage-linked symptoms may provide a more clinically informative understanding of NPS in AD.

  • Open Access

    Behavioral Complexity in Alzheimer’s Disease: A Diversity-Based Analysis of Neuropsychiatric Symptoms

    by YoungSoon Yang, Yong Tae Kwak

    Background and Objectives: To quantify behavioral complexity in probable Alzheimer’s disease (AD), compare complexity phenotypes, and determine whether behavioral complexity provides clinically meaningful information beyond total neuropsychiatric burden. We also explored whether global amyloid extent and lobar amyloid topography added explanatory value. Methods: In this cross-sectional retrospective study, we analyzed 245 psychotropic drug-naïve patients with probable AD, positive 18F-FC119S amyloid positron emission tomography (PET), and complete neuropsychiatric, cognitive, functional, and regional PET data. Behavioral complexity was derived from 12 Korean Neuropsychiatric Inventory domains using symptom count, normalized Shannon entropy of the frequency × severity profile, and a composite index. Patients were classified into tertiles. Multivariable regression and burden-stratified analyses examined associations with cognition, dementia severity, function, and amyloid measures. Results: Higher behavioral complexity was associated with lower Korean Mini-Mental State Examination (K-MMSE) scores and higher Clinical Dementia Rating (CDR) and Global Deterioration Scale (GDS) stages. In multivariable analysis, higher CDR, higher GDS, and lower Barthel Index independently predicted greater complexity, whereas amyloid extent did not. After adjustment for total neuropsychiatric burden, higher CDR remained independently associated with the composite complexity index and normalized entropy, while amyloid extent remained non-significant. Complexity-related clinical differences were most evident in the lowest burden stratum and attenuated at higher burden levels. Regional amyloid analyses yielded only selective signals. Conclusions: Behavioral complexity is a clinically meaningful neuropsychiatric phenotype in AD. Although strongly related to total neuropsychiatric burden, it is not fully reducible to it, with its clearest independent association seen for global dementia severity, particularly at lower overall burden.

  • Open Access

    Stage-dependent reorganization of amyloid PET region–symptom bipartite networks in drug-naïve, amyloid-positive Alzheimer’s disease

    by Youngsoon Yang, Yong Tae Kwak

    Management of neuropsychiatric symptoms (NPS) is pivotal to care in Alzheimer's disease (AD), yet their alignment with amyloid topology may vary by stage. We examined whether the community (modular) structure of a brain-region-symptom co-occurrence network differs by clinical stage, testing the hypothesis that modular organization is more pronounced in earlier AD and becomes less segregated with increasing severity. In a cross-sectional retrospective cohort from a tertiary dementia clinic, we included 301 consecutive, drug-naïve patients with probable AD and amyloid-positive PET (18F-FC119S). Patients were stratified by Clinical Dementia Rating (CDR 0.5, n = 38; CDR 1.0, n = 107; CDR 2.0, n = 156). We built bipartite networks linking six cortical regions (bilateral frontal, temporal, parietal; PET positivity from automated SUVRs) to 12 Korean Neuropsychiatric Inventory (K-NPI) domains (presence = frequency × severity ≥ 1). Network density, community structure (Louvain modularity with 2000 within-symptom permutations), node strength/centralities, and stage-matched backbones were assessed. The pooled network was dense and non-modular. Stage-stratified analyses revealed significant modularity at CDR 0.5 only, with increasing density from CDR 0.5 to 2.0 and loss of community structure thereafter. Left temporal and left frontal cortices emerged as consistent regional hubs, while parietal contributions were minimal. On the symptom side, aggression and delusion carried the largest co-occurrence burdens, followed by disinhibition and anxiety; findings were robust across backbone and sensitivity analyses. These results support a stage-dependent reorganization from modest, symptom-specific modularity in early stage AD to diffuse, hub-centric coupling in later stages. Recognizing this transition may reconcile prior inconsistencies and inform clinical strategy: targeted, domain-focused interventions when modularity persists versus global stabilization as networks densify, with implications for enrichment and endpoint selection in NPS-focused trials.


  • Open Access

    Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?

    by YoungSoon Yang, Yong Tae Kwak

    Ginkgo biloba products have been used for decades for cognitive symptoms, yet the clinical evidence in Alzheimer’s disease (AD) remains modest and heterogeneous. This review revisits key symptomatic and prevention trials and summarizes how systematic reviews and meta-analyses have informed ongoing clinical skepticism, often citing small effect sizes, limited patient-centered meaningfulness, short follow-up, and repeated trial designs. We suggest that long-standing ambiguity reflects multiple, overlapping sources of heterogeneity, including mixed-pathology recruitment, variable dosing and exposure duration, inconsistent outcome frameworks, and limited integration of biological readouts; differences across preparations and characterization practices may further contribute to variability. In the biomarker era, AD is increasingly defined biologically, and amyloid PET-confirmed cohorts offer a clearer test by reducing diagnostic noise and enabling mechanism-adjacent interpretation. Recent studies in amyloid PET-positive MCI/AD report clinical preservation alongside directional changes in plasma oligomerization tendency (MDS-OAβ), with decreases in treated groups compared with increases in controls. While such findings cannot, by design, establish disease-modifying effects, they provide a biologically anchored context for interpreting modest clinical signals. We conclude with practical recommendations to align cohort biology, stage, exposure certainty, duration, endpoints, and biomarker panels in next-generation trials of Ginkgo preparations in early AD-spectrum disease.

  • Ginkgo biloba and longitudinal changes in amyloid PET and plasma amyloid-β oligomerization in amyloid-positive mild cognitive impairment: A retrospective analysis

    by YoungSoon Yang, Yong Tae Kwak

    Background: Amyloid PET–positive mild cognitive impairment (MCI) is a prodromal stage of Alzheimer's disease (AD), but its longitudinal clinical and biomarker trajectories vary considerably. Evidence linking oral interventions to amyloid-related biomarkers in this population remains limited. Objective: To compare 18-month clinical outcomes and longitudinal changes in plasma amyloid-β (Aβ) oligomerization tendency and amyloid PET burden according to Ginkgo biloba use in amyloid PET–positive MCI. Methods: This retrospective cohort study included 35 amyloid PET–positive MCI patients who underwent baseline and 18-month clinical evaluations, serial plasma Aβ oligomerization measurements using the Multimer Detection System–Oligomerized Aβ (MDS-OAβ) assay, and paired baseline and 18-month 18 F-FC119S amyloid PET. Patients received Ginkgo biloba extract 240 mg/day (n = 21) or Non-Ginkgo cognitive enhancers (n = 14). Clinical stability, conversion to AD dementia (Korean Instrumental Activities of Daily Living ≥0.40), changes in MDS-OAβ, and changes in global cortical standardized uptake value ratio (SUVR) were assessed. Results: Baseline characteristics were comparable between groups. At 18 months, all Ginkgo-treated patients remained clinically stable, whereas 57.1% of Non-Ginkgo patients showed cognitive decline. Conversion to AD dementia occurred in none of the Ginkgo group and in 28.6% of the Non-Ginkgo group. Plasma MDS-OAβ decreased with Ginkgo but increased without Ginkgo. Global amyloid PET SUVR remained stable in the Ginkgo group and increased in the Non-Ginkgo group. Conclusions: In amyloid PET–positive MCI, Ginkgo biloba use was associated with sustained clinical stability, reduced plasma Aβ oligomerization tendency, and attenuation of amyloid PET progression over 18 months.


  • Open Access

    Dual-threshold plasma Aβ oligomerization for postoperative delirium risk stratification

    by YoungSoon Yang, Ki Jin Jung, Yong Tae Kwak

    Background: Postoperative delirium is common in older surgical patients, but simple blood tests to identify risk are lacking. Plasma amyloid-β oligomers measured by multimer detection (MDS-OAβ) may reflect neurodegenerative vulnerability. Methods: We enrolled 101 patients aged ≥65 years undergoing elective orthopaedic surgery with general anaesthesia. Blood was drawn preoperatively and at first delirium diagnosis or on postoperative Day 4 if no delirium. MDS-OAβ was quantified blinded. Delirium was assessed daily on postoperative Days 1–3 (DRS-R-98 and DSM). Propensity-score matching on APOE ε4 status and clinical covariates addressed Alzheimer-type vulnerability. Discrimination and thresholds (0.60, 0.72, 0.85 ng/ml) were evaluated using logistic regression and ROC analyses. Results: Among 101 patients (44 with delirium; 57 without), preoperative MDS-OAβ concentrations were higher in those who developed delirium and correlated with delirium severity. In the overall cohort, preoperative MDS-OAβ discriminated delirium with an area under the curve of 0.855 (95% CI 0.777–0.919); in a pooled postoperative dataset (n = 205), discrimination was similar (AUC 0.884, 95% CI 0.837–0.925). The dual-threshold approach identified a low-risk group with high negative predictive value and a high-risk group with high positive predictive value, leaving an intermediate group for closer observation. Conclusions: Preoperative plasma MDS-OAβ may provide a scalable biomarker for perioperative risk stratification of postoperative delirium in older adults, supporting a dual-threshold strategy for targeted prevention and monitoring. Low MDS-OAβ values indicate lower risk but do not exclude POD; biomarker-guided stratification should complement, not replace, routine perioperative delirium surveillance.

  • Open Access

    A Multi-Axis Framework for Late-Life Alzheimer’s Disease Interpretation

    by Yong Tae Kwak, YoungSoon Yang

    Late-life Alzheimer’s disease (AD) is increasingly defined by biomarkers, yet in adults aged ≥65 years the relationship between amyloid positivity and near-term cognitive decline is often discordant. Amyloid PET robustly detects fibrillar plaque burden, but it incompletely captures dynamic and potentially neurotoxic amyloid processes, particularly soluble assemblies and oligomer-related “activity.” This review rethinks the late-life AD spectrum by integrating four clinical lenses that frequently drive real-world interpretive uncertainty: (1) amyloid PET positivity as a measure of fibrillar plaque presence and magnitude; (2) plasma amyloid-β oligomerization tendency measured by the multimer detection system (MDS-OAβ) as an activity-oriented (i.e., a dynamic readout hypothesized to reflect ongoing processes rather than cumulative lesion burden), process-linked readout that may decouple from plaque burden; (3) postoperative delirium (POD) as a time-anchored stress-test phenotype revealing vulnerability and reduced resilience under systemic insults; and (4) drug-linked biomarker trajectories, contrasting rapid plaque removal by anti-amyloid monoclonal antibodies with observational signals raising the hypothesis that Ginkgo biloba may be associated with oligomer-related biology and, in some contexts, differences in longitudinal amyloid accumulation trajectories in the absence of observed immediate plaque reduction. We propose a pragmatic multi-axis framework—plaque burden, amyloid activity, downstream engagement, and vulnerability/resilience—to contextualize late-life discordances such as PET positivity without decline, PET negativity with elevated MDS-OAβ, delirium-associated decompensation, and clinical change without rapid PET decline. This synthesis highlights testable predictions and prioritizes longitudinal, multi-marker studies to determine whether activity-oriented biomarkers and stress phenotypes can refine late-life risk stratification beyond plaque-centered models.

  • Open Access

    Six-month randomized, double-blind trial of transcranial direct current stimulation in mild Alzheimer's dementia: domain-specific cognitive and neuropsychiatric signals

    by YoungSoon Yang, Youngmin Huh, Kiwon Lee, Yong Tae Kwak

    Background: Prefrontal transcranial direct current stimulation (tDCS) is a low-risk candidate intervention for cognitive enhancement in Alzheimer's disease (AD), but trial results are heterogeneous and often short-term. We evaluated the 26-week efficacy, safety, and family-level impact of home-based prefrontal tDCS in mild AD. Methods: In this randomized, double-blind, sham-controlled trial, 120 patients with mild AD were allocated to active ( n = 59) or sham ( n = 61) tDCS. The intention-to-treat (ITT) population included 106 participants (53 vs. 53) with post-baseline data; 66 (32 vs. 34) comprised the per-protocol (PP) set. The primary outcome was change in global cognition on the Korean Mini-Mental State Examination (K-MMSE). Secondary and exploratory outcomes included domain-specific cognition [e.g., Korean Boston Naming Test (K-BNT)], neuropsychiatric symptoms [Korean Neuropsychiatric Inventory (K-NPI)], patient quality of life (QoL-AD), and caregiver-reported family quality of life [Family Quality of Life–Dementia (FQoL-D)]. Adverse events (AEs) were systematically monitored. Results: K-MMSE declined slightly in both groups over 26 weeks (active Δ −0.53, sham Δ −0.15), with no significant between-group difference ( p = 0.402). Most cognitive domains showed small, non-significant changes. In contrast, confrontation naming on the K-BNT favored active tDCS: in ITT analyses, naming performance was stable with active stimulation (Δ +0.51) but worsened with sham (Δ −2.32; p = 0.022), with a similar pattern in the PP set. K-NPI findings were inconsistent across analytic sets. Notably, FQoL-D declined in the active arm but improved in the sham arm in both ITT (Δ −2.19 vs. +1.94; p = 0.043) and PP analyses. Overall AE rates were similar; stimulation-site reactions were common but mild, and serious AEs were rare and deemed unrelated to tDCS. Conclusion: In mild AD, 26 weeks of home-based prefrontal tDCS did not improve global cognition vs. sham, although a modest benefit in confrontation naming was observed. The deterioration in caregiver-reported family quality of life highlights the need to weigh potential cognitive gains against family burden in long-term home-based neuromodulation. Clinical trial registration: Clinical Research Information Service (CRIS), KCT0005834.